AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Innovative vaccine now in trials for advanced cancer patients.(Brief Article)
2002 JUN 26 - (NewsRx.com & NewsRx.net) -- An original procedure to perform a vaccination of cancer patients with a composition prepared with their own blood has been developed by PharmaBlood, a company with headquarters in Florida.
The vaccine includes a pretreatment of the patient in order to reach high blood levels of tumor-released specific molecules or tumor antigens. A sample of patient's blood is further submitted to laboratory procedures to improve its antigenicity prior to being reinjected to the patient. In addition, the patient's immune system is conditioned for an empowered immune response. The procedure includes an internal vaccination performed by high production and release of tumor antigens inside the patient, followed by an external vaccination, performed by reinjection of a tumor antigens composition obtained from patient's blood. As with other described autologous tumor vaccinations, this is a personalized treatment because each patient is vaccinated with the antigens of its own tumor.
The new procedure is innovative by two characteristics: 1) pretreating patients in order that their tumors become more antigenic for the hosts is an absolutely new approach to ...
- Regulatory T cells may have a role in poor immune response against tumor...
- Newspaper article from: Vaccine Weekly November 27, 2002 700+ words
...immunogenicity of tumor antigens may be due to...in 35 breast cancer patients, 30 pancreas cancer patients, and 35 healthy...and pancreas cancer patients (13.2...response against tumor antigens." The corresponding...
- Regulatory T cells may have a role in poor immune response against tumor...
- Newspaper article from: Cancer Weekly November 26, 2002 700+ words
...immunogenicity of tumor antigens may be due to...in 35 breast cancer patients, 30 pancreas cancer patients, and 35 healthy...and pancreas cancer patients (13.2...response against tumor antigens." The corresponding...
- 'Commercializing on Tumor Antigens: Analytical Perspectives'; - New 'de-novo'...
- Press release article from: PR Newswire May 14, 2002 700+ words
...a new report, "Commercializing On Tumor Antigens: Analytical Perspectives", that...report we have identified more than 60 tumor antigens that are in line for commercialization...an updated summary of the field of tumor antigens today, for example discussing the...
- Research and Markets: Commercializing on Tumor Antigens: Analytical...
- Press release article from: Business Wire July 14, 2004 700+ words
DUBLIN, Ireland -- Tumor Antigens Industry, Worth an Estimated...addition of Commercializing on Tumor Antigens: Analytical Perspectives to...analyst at a VC firm. More than 60 tumor antigens have been identified that are...
- Transfection of tumor antigens generates cytotoxic T lymphocytes.
- Newspaper article from: Biotech Week August 4, 2004 700+ words
...amp; NewsRx.net) -- Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged...study in Molecular Therapy (Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged...
- RNA-transfected cells induce responses against viral and tumor antigens.
- Newspaper article from: Health & Medicine Week May 3, 2004 700+ words
...necessity of HLA matching," stated Christina M. Coughlin and colleagues at the University of Pennsylvania. "For viral and tumor antigens, CD40-B/RNA technology induced cytotoxic T lymphocytes (CTLs) from adults and children, which could be identified...
- Method for identifying new tumor antigens developed.
- Newspaper article from: Genomics & Genetics Weekly April 4, 2003 700+ words
2003 APR 4 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX; GX1) announced that it has added to its technology portfolio by expanding the license with the University of British Columbia in Vancouver, Canada. The added technology, developed under the Collaborative Research Agreement between
- Esdifan debuts.(CVS Corp. unveils tumor antigens)(Brief Article)
- Magazine article from: Chain Drug Review November 21, 2005 700+ words
CVS Corp. has begun carrying Esdifan, a natural remedy targeted to those who suffer from irritable bowel syndrome. The product, from ZEO Health Ltd., is also on store shelves at outlets operated by Happy Harry's Inc.
